Cantab receives funding from Celtic Pharma investment fund
This article was originally published in Scrip
Executive Summary
Cantab Biopharmaceuticals is to receive £5 million over three years from its owner, Celtic Pharma's investment fund, Celtic Pharma Holdings II (CP2).